2. GPCR/G Protein TGF-beta/Smad
  3. Endothelin Receptor TGF-β Receptor
  4. Sitaxsentan

Sitaxsentan  (Synonyms: IPI 1040; TBC-11251)

製品番号: HY-76520
取扱説明書 Technical Support

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Sitaxsentan

Sitaxsentan 構造式

CAS 番号 : 184036-34-8

容量 価格（税別） 在庫状況 数量
5 mg $200 お問い合わせ 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
10 mg $320 お問い合わせ 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
25 mg $640 お問い合わせ 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
50 mg $960 お問い合わせ 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
100 mg $1440 お問い合わせ 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
200 mg   お問い合わせ  
500 mg   お問い合わせ  
Synthetic products have potential research and development risk.

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Other Forms of Sitaxsentan:

Sitaxsentan 関連抗体

Top Publications Citing Use of Products

Endothelin Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
ETA ETB

TGF-β Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension[1][2][3][4][5].

IC50 & Target[4]

ETA

1.4 nM (IC50)

ETA

0.43 nM (Ki)

ETB

9800 nM (IC50)

体外実験

Sitaxsentan (100 μM, 10 min) significantly inhibits taurocholate cotransporter (NTCP) and organic anion transporter (OATP) transportation in sandwich-cultured human hepatocytes[3].
Sitaxsentan (10 min) has a high efficiency of liver cell uptake and almost no bile excretion[3].
Sitaxsentan has moderate hepatobiliary transporters bile salt export pump (BSEP) inhibition (IC50 = 25 μM) in sandwich-cultured human hepatocytes[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sitaxsentan 関連抗体
体内実験

Sitaxsentan (1.5 mg/kg, p.o., three times a day for 3 months) effectively prevents PAH caused by shunt induction, and the combined medication with Sildenafil (HY-15025) has a better effect in piglets[1].
Sitaxsentan (5 mg/kg, i.v., single dose) completely blocks the activation of ETA receptors in the acute hypoxia model of rats[2].
Sitaxsentan (15-30 mg/kg, p.o., once daily for 2-4 weeks) significantly improves PAH and vascular remodeling caused by chronic hypoxia, but has limited effect on the already formed right ventricular hypertrophy in rat chronic hypoxia model[2].
Sitaxsentan (10-50 mg/kg, p.o., once daily for 3 weeks) dose-dependently improves Monocrotaline(HY-N0750)-induced pulmonary hypertension in rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Shunt-induced PAH model established in piglets (18 days old, 5.3 kg)[1]
Dosage: 1.5 mg/kg or 1.5 mg/kg combined with 0.75 mg/kg Sildenafil
Administration: Oral administration (p.o.) with food, three times a day for 3 months
Result: Combined treatment completely restored the normal state.
Partially inhibited the thickening of blood vessels with single-drug and the combined therapy almost completely prevented it.
Partially restored the expression of BMPR-1A and BMPR-2.
Maintained normal right ventricle-aorta coupling.
Animal Model: Acute hypoxia induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 5 mg/kg
Administration: Intravenous injection (i.v.), 10 minutes before or 50 minutes after the onset of hypoxia
Result: Completely blocked the increase in pressure in prevention group.
Rapidly reversed the elevated MPAP after administration of the drug (reaching normal levels within approximately 30 minutes) in treatment group.
Animal Model: Chronic hypoxia induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 15 mg/kg in prevention group and 15 mg/kg and 30 mg/kg in treatment group
Administration: Oral administration (p.o.) with water, once daily, 48 hours before hypoxia and lasting for 2 weeks or after 2 weeks of hypoxia and lasted for 4 weeks
Result: Decreased The MPAP in the prevention group by 35%, and in the treatment group decreased by 38%.
Reduced the ratio of RV/(LV + S) to some extent.
Improved pulmonary vascular remodeling in both groups.
Animal Model: Monocrotaline induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 10 and 50 mg/kg
Administration: Oral administration (p.o.) with water, once daily for 3 weeks
Result: Improved hemodynamic conditions.
Almost completely prevented pulmonary vascular remodeling at high dose (50mg/kg).
臨床実験
分子量

454.90

分子式

C18H15ClN2O6S2
CAS 番号
SMILES

O=S(C1=C(C(CC2=CC3=C(C=C2C)OCO3)=O)SC=C1)(NC4=C(C(C)=NO4)Cl)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sitaxsentan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sitaxsentan184036-34-8IPI 1040 TBC-11251IPI1040IPI-1040TBC11251TBC 11251TBC-11251Endothelin ReceptorTGF-β ReceptorTransforming growth factor beta receptorsportopulmonary hypertensionbone morphogenetic protein receptor-1Apulmonary arterial hypertensionBMPR-2CYP3A4CYP2C9endothelin A receptorendothelin B receptorsendothelin-1hepatocytesInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Sitaxsentan
製品番号:
HY-76520
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.